Pharmaceuticals

NLS Pharmaceutics

NLS and Kadimastem Merge to Form NewCelX and Expand DOXA Platform

NLS and Kadimastem Merge to Develop Type 1 Diabetes Cell Therapy Project

NLS Pharmaceutics released FY2025 Q2 earnings on October 6 (EST), actual revenue USD 0, actual EPS USD -0.2674

NLS Pharmaceutics released FY2025 Semi-Annual Earnings on October 6 (EST), with actual revenue of USD 0 and EPS of USD -1.0469

NLS Pharmaceutics released FY2025 Q1 earnings on October 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.5234

NLS Pharmaceutics Receives Milestone Funding Support from BIRD Foundation

NLS Pharmaceutics Completes $1 Million Equity Financing

NLS Pharmaceutics to Present New Preclinical Data on Mazindol ER at ASCP Annual Meeting

NLS Pharmaceutics released FY2024 9 Months Earnings on May 16 (EST), actual revenue USD 0, actual EPS USD -2.4373

NLS Pharmaceutics released FY2024 Q4 earnings on May 16 (EST), actual revenue USD 0, actual EPS USD -0.4958

NLS Pharmaceutics released FY2024 Q3 earnings on May 16 (EST), actual revenue USD 0, actual EPS USD -0.4958

NLS Pharmaceutics released FY2024 Annual Earnings on May 16 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.6288 (forecast USD -1.6)

NLS Pharmaceutics Announces Positive Results for Mazindol Study

NLS Pharmaceutics AG released Q1 2024 earnings on October 18, 2024, with EPS -1.9414 USD and no revenue

NASDAQ Committee Approves NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements.

NLS Pharmaceuticals Signs Additional Bridge Loan Supplement Extending Loan Maturity to June 30, 2025

NLS Pharmaceutics released FY2023 Q3 earnings on May 15, 2024 (EST), with actual revenue of USD 0 and EPS of USD -2.3885

NLS Pharmaceutics released FY2023 Q4 earnings on May 15, 2024 (EST) with actual revenue of USD 0 and EPS of USD -2.3885

NLS Pharmaceutics released FY2023 9 Months Earnings on May 15, 2024 (EST) with actual revenue of USD 0 and EPS of USD -10.365

NLS Pharmaceuticals Receives Delisting Notice from Nasdaq

Liminatus Pharma

NewGenIvf

Co-Diagnostics

Agape ATP

Tradr 2X Long QBTS Daily ETF

Sunshine Biopharma

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

Wheeler Real Estate

Tradr 2X Long APLD Daily ETF

APGE

NLSP

SBIO

AgomAb Therapeutics NV has announced the launch of its initial public offering (IPO) of 12,500,000 American Depositary Shares (ADSs), with an estimated price range of $15.00 to $17.00 per ADS. The company aims to list its ADSs on the Nasdaq Global Market under the symbol "AGMB". The offering includes a 30-day option for underwriters to purchase an additional 1,875,000 ADSs. J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen are acting as joint book-running managers. A registration statement has been filed with the SEC, and the final terms will be disclosed in a prospectus.

fidelity

Apogee Therapeutic

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

LAVA Therapeutics NV

VG Health

Invesco Biotechnology & Genome ETF

iShares US Pharma

Newamsterdam Pharma

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

VanEck Biotech ETF

SPDR S&P Biotech

Agomab Announces Launch of Initial Public Offering

NLS Pharmaceutics (NLSP) announced the expansion of its DOXA platform with the AEX-6xx series, developed with Aexon Labs, targeting arousal stability, cognition, and neuroprotection for conditions like Parkinson’s disease. This expansion aligns with its merger with Kadimastem to form NewCelX. The company secured $25 million in funding for future clinical programs. NLS Pharmaceutics focuses on therapies for CNS and neurodegenerative disorders and will be listed on Nasdaq as NewCelX Ltd. with a market cap of $3.15M.

Tip Ranks

NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series

NLS Pharmaceutics pre-market up 10.12%; Cleveland Cliffs pre-market down 9.58%;

Price Alert

Cleveland Cliffs

Pre-market hot trades in the US stock market: NLS Pharmaceutics up 10.12% in pre-market; Cleveland Cliffs down 9.58% in pre-market

NLS Pharmaceutics shares are trading lower after the company announced its plans to effect a reverse share split at 1-for-10, effective October 31.

benzinga_article

NCEL

NLS Pharmaceutics and Kadimastem have announced the continuation of the ITOL-102 diabetes program following their merger into NewCelX Ltd. This program focuses on developing a stem-cell-derived therapy for Type 1 Diabetes, aiming to eliminate the need for lifelong immunosuppression. The initiative is supported by the BIRD Foundation and represents NLS's strategic move into regenerative medicine. NLS Pharmaceutics specializes in therapies for CNS disorders, while Kadimastem develops cell products for neurodegenerative diseases and diabetes. Current market cap is $4.46M with a trading volume of 676,799.

NewcelX

NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger

NLS Pharmaceutics(NLSP.US)

Agomab Announces Launch of Initial Public Offering

NLS Pharmaceutics Expands CNS Pipeline with AEX-6xx Series

Pre-market hot trades in the US stock market: NLS Pharmaceutics up 10.12% in pre-market; Cleveland Cliffs down 9.58% in pre-market

NLS Pharmaceutics shares are trading lower after the company announced its plans to effect a reverse share split at 1-for-10, effective October 31.

NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger